A Phase 2 Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous ANX005 in Patients With, or at Risk for, Manifest Huntington’s Disease (HD)

A Phase 2 Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous ANX005 in Patients With, or at Risk for, Manifest Huntington’s Disease (HD) - Annexon Biosciences